menu
    • menu

    Company profile for Pfizer Inc

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across...
    At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative bioph

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Pfizer IncUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    235 East 42nd Street New York, NY 10017
    Telephone
    Telephone
    +1 212-733-2323
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.pfizer.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/pfizer/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Pfizer

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    This week, SpeakPharma interviews Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. Sutton has been with the company for over 25 years. In this interview, she provides insights into the evolution of Quotient Sciences’ Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. She also shares her perspective on the company’s unique approach to integrating drug development services. HIGHLIGHTS// evolution of Quotient Sciences’ Nottingham facility/ unique approach to integrating drug development services How has the Nottingham site transformed from when it was founded, to what it is today? Initially, we were a small company with fewer than 50 employees, a 10-bed clinic, and a single lab. Over 90 percent of our work focused on gamma scintigraphic imaging (a diagnostic test that creates images of the body’s internal organs and tissues using gamma rays). Due to the short half-life radionuclides we used to label dosage forms, every product we manufactured had a limited time to be dosed. At the end of 1999, we moved our headquarters to a purpose-built, two-storey facility—now known as Trent House on our now much larger Nottingham campus. We built three good manufacturing practice (GMP) suites on the top floor and three clinical wards on the bottom floor. These were very early days that marked the start of our Translational Pharmaceutics platform. We continued to expand the range of scintigraphy applications we offered in response to changing customer requirements until, in 2008, when we approached the MHRA (UK’s Medicines and Healthcare products Regulatory Agency) with a new request. We asked if it might be possible to work at the same pace as we did in our scintigraphic imaging studies, but do so for conventional drug development, without the radiolabel. We explored the application of ICH Q8 Quality by Design (QbD) guidelines to introduce a compositional design space into the CMC section of our regulatory dossier. This officially created a methodology for applying the Translational Pharmaceutics platform, and we haven't looked back since. Today, we have expanded substantially. Our Nottingham site is a campus of five buildings. We have development and analytical labs, six GMP suites, six clinical wards with a total of 85 beds (where we conduct healthy volunteer phase 1 clinical studies), and many talented colleagues covering our spectrum of CRO and CDMO services. HIGHLIGHTS// officially created a methodology for applying the Translational Pharmaceutics platform/ development and analytical labs/ six GMP suites   How is Translational Pharmaceutics applied to drug development programs? We apply Translational Pharmaceutics across three core applications: first-in-human clinical studies, drug product optimization programs through rapid formulation development and clinical testing, and as a part of human ADME (absorption, distribution, metabolism, and excretion) programs. No matter how a client chooses to work with us to apply Translational Pharmaceutics, the benefits of using a single organization and project management team to integrate services lets our clients remain in control and one step ahead of the emerging data that impacts the success of their molecule. Over all these years, our flagship Translational Pharmaceutics platform for drug development has remained unchanged in the way it empowers our customers and offers them unparalleled flexibility. HIGHLIGHTS// three core applications/ benefits of using a single organization/ clients remain in control   What would you say are the key strengths of Quotient Sciences’ Nottingham site? How do you support customer programs? Nowhere else would a single project manager oversee such a broad spectrum of activities, let alone be expected to ensure seamless, timely progression across functions that in any other company (i.e. at other CDMOs or CROs) would be delivered through multiple operating areas or through the use of a combination of third-party vendors. The project managers do face challenges. But by working with the project team, they are able to anticipate, avoid, and mitigate any impact whenever necessary. We know that time is incredibly valuable for our customers. A project Gantt chart is our project management team’s guiding light. I believe our project management team is truly world-leading – they communicate well, show great compassion, and lead with integrity. I’m super proud of our high-performing, supportive, cross-functional teams that support our customers when they trust their molecules to us, and work collaboratively to deliver the best possible service. After 25 years at Quotient, I continue to really enjoy going to work. I am indebted to various colleagues for helping me continue to feel this way. HIGHLIGHTS// project management team is truly world-leading/ high-performing, supportive, cross-functional teams/ 25 years at Quotient  

    Impressions: 303

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

    Radio Compass
    16 Dec 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 11518

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer doesn't expect major vaccine policy changes in 2025
    Pfizer doesn't expect major vaccine policy changes in 2025

    18 Dec 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-forecasts-2025-profit-line-with-expectations-2024-12-17/

    REUTERS
    18 Dec 2024
    Share Share
    Pfizer Declares First-Quarter 2025 Dividend
    Pfizer Declares First-Quarter 2025 Dividend

    12 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241211645444/en

    BUSINESSWIRE
    12 Dec 2024
    Share Share
    Pfizer’s Ibrance Improves Survival in New Breast Cancer Indication
    Pfizer’s Ibrance Improves Survival in New Breast Cancer Indication

    12 Dec 2024

    // BIOSPACE

    https://www.biospace.com/drug-development/pfizers-ibrance-improves-survival-in-new-breast-cancer-indication

    BIOSPACE
    12 Dec 2024
    Share Share
    Lilly CEO says tax & Regulation reform, drug affordability focuses
    Lilly CEO says tax & Regulation reform, drug affordability focuses

    11 Dec 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-ceo-says-tax-regulation-reform-drug-affordability-are-focuses-under-trump-2024-12-10/

    REUTERS
    11 Dec 2024
    Share Share
    Amazon, Pfizer, RFK Jr Discuss Climate Health Risks Collaboration
    Amazon, Pfizer, RFK Jr Discuss Climate Health Risks Collaboration

    11 Dec 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/amazon-pharmacy-exec-hopeful-rfk-jr-is-an-ally-2024-12-11/

    REUTERS
    11 Dec 2024
    Share Share
    Pfizer Webcast On Dec 17 For 2025 Financial Guidance
    Pfizer Webcast On Dec 17 For 2025 Financial Guidance

    10 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241210056613/en

    BUSINESSWIRE
    10 Dec 2024
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zai Lab and Pfizer Collaborate on XACDURO® for Novel Antibacterial Applications

    Details:

    The collaboration aims for the commercialisation of novel antibacterial drug Xacduro (sulbactam-durlobactam) for the treatment of carbapenem-resistant Acinetobacter baumannii, in mainland China.


    Lead Product(s): Sulbactam,Durlobactam

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Xacduro

    Study Phase: ApprovedProduct Type: Small molecule

    Recipient: Zai Lab

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration November 21, 2024

    blank

    01

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sulbactam,Durlobactam

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Recipient : Zai Lab

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Zai Lab and Pfizer Collaborate on XACDURO® for Novel Antibacterial Applications

    Details : The collaboration aims for the commercialisation of novel antibacterial drug Xacduro (sulbactam-durlobactam) for the treatment of carbapenem-resistant Acinetobacter baumannii, in mainland China.

    Brand Name : Xacduro

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    November 21, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    EU Approves Pfizer’s HYMPAVZI™ for Severe Hemophilia A/B Without Inhibitors

    Details:

    Hympavzi (marstacimab) is a human mAb IgG1 that targets TFPI approved as a subcutaneous treatment for severe hemophilia A or moderately severe to severe hemophilia B in 12 years and above patients.


    Lead Product(s): Marstacimab

    Therapeutic Area: Genetic Disease Brand Name: Hympavzi

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 20, 2024

    blank

    02

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Marstacimab

    Therapeutic Area : Genetic Disease

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    EU Approves Pfizer’s HYMPAVZI™ for Severe Hemophilia A/B Without Inhibitors

    Details : Hympavzi (marstacimab) is a human mAb IgG1 that targets TFPI approved as a subcutaneous treatment for severe hemophilia A or moderately severe to severe hemophilia B in 12 years and above patients.

    Brand Name : Hympavzi

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    November 20, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    TRIANA and Pfizer Partner to Discover Novel Molecular Glue Degraders

    Details:

    The collaboration aims to discover novel molecular glue degraders for multiple targets in several disease areas, including oncology.


    Lead Product(s): Undisclosed

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Discovery PlatformProduct Type: Small molecule

    Recipient: TRIANA Biomedicines

    Deal Size: $1,549.0 million Upfront Cash: $49.0 million

    Deal Type: Collaboration October 15, 2024

    blank

    03

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Highest Development Status : Discovery Platform

    Recipient : TRIANA Biomedicines

    Deal Size : $1,549.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    TRIANA and Pfizer Partner to Discover Novel Molecular Glue Degraders

    Details : The collaboration aims to discover novel molecular glue degraders for multiple targets in several disease areas, including oncology.

    Brand Name : Undisclosed

    Molecule Type : Small molecule

    Upfront Cash : $49.0 million

    October 15, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    IsomAb and Pfizer Partner on PAD Development Candidate Collaboration

    Details:

    IsomAb collaborates with Pfizer Ignite to support preclinical development and IND-enabling studies for ISM-001 for the treatemnt of chronic limb threatening ischaemia.


    Lead Product(s): ISM-001

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: ISM-001

    Study Phase: PreclinicalProduct Type: Large molecule

    Recipient: IsomAb

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration October 15, 2024

    blank

    04

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ISM-001

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Preclinical

    Recipient : IsomAb

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    IsomAb and Pfizer Partner on PAD Development Candidate Collaboration

    Details : IsomAb collaborates with Pfizer Ignite to support preclinical development and IND-enabling studies for ISM-001 for the treatemnt of chronic limb threatening ischaemia.

    Brand Name : ISM-001

    Molecule Type : Large molecule

    Upfront Cash : Undisclosed

    October 15, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Approves Pfizer’s HYMPAVZI™ For Hemophilia A Or B Without Inhibitors

    Details:

    Hympavzi (marstacimab) is a human mAb IgG1 that targets TFPI approved as a subcutaneous treatment for severe hemophilia A or moderately severe to severe hemophilia B in 12 years and above patients.


    Lead Product(s): Marstacimab

    Therapeutic Area: Genetic Disease Brand Name: Hympavzi

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 11, 2024

    blank

    05

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Marstacimab

    Therapeutic Area : Genetic Disease

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    FDA Approves Pfizer’s HYMPAVZI™ For Hemophilia A Or B Without Inhibitors

    Details : Hympavzi (marstacimab) is a human mAb IgG1 that targets TFPI approved as a subcutaneous treatment for severe hemophilia A or moderately severe to severe hemophilia B in 12 years and above patients.

    Brand Name : Hympavzi

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    October 11, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Strong Cresemba® Sales in Asia Trigger Milestone Payment to Basilea

    Details:

    Cresemba (isavuconazonium sulfate) is the prodrug of isavuconazole which is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.


    Lead Product(s): Isavuconazonium Sulfate

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Cresemba

    Study Phase: ApprovedProduct Type: Small molecule

    Recipient: Basilea Pharmaceutica

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement October 10, 2024

    blank

    06

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Isavuconazonium Sulfate

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Recipient : Basilea Pharmaceutica

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Strong Cresemba® Sales in Asia Trigger Milestone Payment to Basilea

    Details : Cresemba (isavuconazonium sulfate) is the prodrug of isavuconazole which is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.

    Brand Name : Cresemba

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    October 10, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Biohaven Initiates Pivotal Trial of Novel Investigational Drug For Treatment of Migraine

    Details:

    BHV-2100 is a potentially first-in-class, potent, selective, orally administered TRPM3 antagonist, a novel, non-sedating non-opioid treatment for migraine and pain.


    Lead Product(s): BHV-2100

    Therapeutic Area: Neurology Brand Name: BHV-2100

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 30, 2024

    blank

    07

    Biohaven Pharmaceuticals

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Biohaven Pharmaceuticals

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : BHV-2100

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Biohaven Initiates Pivotal Trial of Novel Investigational Drug For Treatment of Migraine

    Details : BHV-2100 is a potentially first-in-class, potent, selective, orally administered TRPM3 antagonist, a novel, non-sedating non-opioid treatment for migraine and pain.

    Brand Name : BHV-2100

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 30, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Japan Approves PADCEV™ with KEYTRUDA® for Unresectable Urothelial Carcinoma

    Details:

    Padcev (enfortumab vedotin), a nectin-4 inhibitor ADC in combination with keytruda, a PD-1 inhibitor. It is being evaluated for the treatment of locally advanced or metastatic urothelial cancer.


    Lead Product(s): Enfortumab Vedotin,Pembrolizumab

    Therapeutic Area: Oncology Brand Name: Padcev

    Study Phase: ApprovedProduct Type: Large molecule

    Recipient: Astellas Pharma

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 24, 2024

    blank

    08

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Enfortumab Vedotin,Pembrolizumab

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Recipient : Astellas Pharma

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Japan Approves PADCEV™ with KEYTRUDA® for Unresectable Urothelial Carcinoma

    Details : Padcev (enfortumab vedotin), a nectin-4 inhibitor ADC in combination with keytruda, a PD-1 inhibitor. It is being evaluated for the treatment of locally advanced or metastatic urothelial cancer.

    Brand Name : Padcev

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    September 24, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Biohaven Reports Positive Results for Troriluzole in Spinocerebellar Ataxia

    Details:

    BHV-4157 (troriluzole ) is a third-generation novel prodrug that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. It is being evaluated for Spinocerebellar Ataxia.


    Lead Product(s): Troriluzole

    Therapeutic Area: Genetic Disease Brand Name: BHV-4157

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 23, 2024

    blank

    09

    Biohaven Pharmaceuticals

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Biohaven Pharmaceuticals

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Troriluzole

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Biohaven Reports Positive Results for Troriluzole in Spinocerebellar Ataxia

    Details : BHV-4157 (troriluzole ) is a third-generation novel prodrug that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. It is being evaluated for Spinocerebellar Ataxia.

    Brand Name : BHV-4157

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 23, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Valneva and Pfizer Report Positive Phase 2 Booster Results for Lyme Disease Vaccine

    Details:

    VLA15, an alum-adjuvanted intramuscular vaccine, which is currently undergoing clinical development for the treatment of Lyme disease.


    Lead Product(s): VLA15

    Therapeutic Area: Infections and Infectious Diseases Brand Name: VLA15

    Study Phase: Phase IIIProduct Type: Vaccine

    Recipient: Valneva

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 03, 2024

    blank

    10

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : VLA15

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Recipient : Valneva

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Valneva and Pfizer Report Positive Phase 2 Booster Results for Lyme Disease Vaccine

    Details : VLA15, an alum-adjuvanted intramuscular vaccine, which is currently undergoing clinical development for the treatment of Lyme disease.

    Brand Name : VLA15

    Molecule Type : Vaccine

    Upfront Cash : Not Applicable

    September 03, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact PFIZER and get a quotation

    PFIZER is a supplier offers 213 products (APIs, Excipients or Intermediates).

    Find a price of Betamethyl Epoxide bulk with DMF, JDMF offered by PFIZER

    Find a price of Epoprostenol Sodium bulk with DMF, JDMF offered by PFIZER

    Find a price of Methylprednisolone bulk with DMF, CEP offered by PFIZER

    Find a price of Prednisolone bulk with JDMF offered by PFIZER

    Find a price of Atorvastatin bulk with JDMF offered by PFIZER

    Find a price of Dexamethasone bulk with JDMF offered by PFIZER

    Find a price of Estradiol Cypionate bulk with DMF offered by PFIZER

    Find a price of Estramustine Phosphate Sodium bulk with DMF offered by PFIZER

    Find a price of Methylprednisolone Acetate bulk with DMF offered by PFIZER

    Find a price of Alprazolam bulk with CEP offered by PFIZER

    Find a price of Betamethasone bulk offered by PFIZER

    Find a price of Betamethasone Valerate bulk offered by PFIZER

    Find a price of Cabergoline bulk offered by PFIZER

    Find a price of Calicheamicin bulk with DMF offered by PFIZER

    Find a price of CAS 50-28-2 bulk offered by PFIZER

    Find a price of Celecoxib bulk with JDMF offered by PFIZER

    Find a price of Chlormadinone Acetate bulk with JDMF offered by PFIZER

    Find a price of Clindamycin Palmitate bulk with DMF offered by PFIZER

    Find a price of Clindamycin Phosphate bulk with DMF offered by PFIZER

    Find a price of Cortisone bulk offered by PFIZER

    Find a price of Diflorasone bulk offered by PFIZER

    Find a price of Dinoprostone bulk with DMF offered by PFIZER

    Find a price of Doxorubicin Hydrochloride bulk with DMF offered by PFIZER

    Find a price of Flumethasone bulk offered by PFIZER

    Find a price of Fluoxymesterone bulk offered by PFIZER

    Find a price of Glipizide bulk with DMF offered by PFIZER

    Find a price of Hydrocortisone Sodium Succinate bulk with CEP offered by PFIZER

    Find a price of Lincomycin Hydrochloride bulk with DMF offered by PFIZER

    Find a price of Megestrol Acetate bulk with DMF offered by PFIZER

    Find a price of Methylprednisolone bulk offered by PFIZER

    Find a price of Methylprednisolone Hemisuccinate bulk with CEP offered by PFIZER

    Find a price of Piperacillin Sodium bulk offered by PFIZER

    Find a price of Piroxicam bulk with CEP offered by PFIZER

    Find a price of Prednisolone Acetate bulk offered by PFIZER

    Find a price of Progesterone bulk with JDMF offered by PFIZER

    Find a price of Triamcinolone bulk offered by PFIZER

    Find a price of Triamcinolone Acetonide bulk offered by PFIZER

    Find a price of Triamcinolone Diacetate bulk offered by PFIZER

    Find a price of 9-Aminocamptothecin bulk offered by PFIZER

    Find a price of Acecainide bulk offered by PFIZER

    Find a price of Acivicin bulk offered by PFIZER

    Find a price of Amphotericin B bulk offered by PFIZER

    Find a price of Ampicillin Sodium bulk offered by PFIZER

    Find a price of Ampicillin Trihydrate bulk offered by PFIZER

    Find a price of Arginine Vasopressin bulk offered by PFIZER

    Find a price of Arlitene bulk offered by PFIZER

    Find a price of Aspirin bulk offered by PFIZER

    Find a price of Bacampicillin bulk offered by PFIZER

    Find a price of Bacitracin Zinc bulk offered by PFIZER

    Find a price of Benzylpenicillin Sodium bulk offered by PFIZER

    Find a price of Betamethasone Benzoate bulk offered by PFIZER

    Find a price of Betamethasone Dipropionate bulk offered by PFIZER

    Find a price of Carbenicillin Indanyl bulk offered by PFIZER

    Find a price of Carboxylic Acid bulk offered by PFIZER

    Find a price of CAS 71-58-9 bulk offered by PFIZER

    Find a price of Cefixime bulk offered by PFIZER

    Find a price of Cefoperazone Sodium bulk offered by PFIZER

    Find a price of Chloramphenicol Palmitate bulk offered by PFIZER

    Find a price of Chloramphenicol Succinate Acid bulk offered by PFIZER

    Find a price of Chlorhexidine Gluconate bulk offered by PFIZER

    Find a price of Chlorpropamide bulk offered by PFIZER

    Find a price of Chlortetracycline Hydrochloride bulk offered by PFIZER

    Find a price of Chondroitin Sulfate Sodium bulk offered by PFIZER

    Find a price of Clindamycin Hydrochloride bulk offered by PFIZER

    Find a price of Clindamycin Phosphate bulk offered by PFIZER

    Find a price of Cycloheximide bulk offered by PFIZER

    Find a price of Cytarabine bulk offered by PFIZER

    Find a price of Dacarbazine bulk offered by PFIZER

    Find a price of Deferoxamine Mesylate bulk offered by PFIZER

    Find a price of Demeclocycline Hydrochloride bulk offered by PFIZER

    Find a price of Diphenhydramine bulk offered by PFIZER

    Find a price of Doxorubicin Hydrochloride bulk offered by PFIZER

    Find a price of Doxycycline Hyclate bulk offered by PFIZER

    Find a price of Edoxudin bulk offered by PFIZER

    Find a price of Erythromycin bulk offered by PFIZER

    Find a price of Erythromycin Stearate bulk offered by PFIZER

    Find a price of Estradiol bulk offered by PFIZER

    Find a price of Estramustine bulk offered by PFIZER

    Find a price of Ethinyl Estradiol bulk offered by PFIZER

    Find a price of Etodolac bulk offered by PFIZER

    Find a price of Exemestane bulk offered by PFIZER

    Find a price of Fedotozine Tartrate bulk offered by PFIZER

    Find a price of Fludrocortisone Acetate bulk offered by PFIZER

    Find a price of Fluocinolone Acetonide bulk offered by PFIZER

    Find a price of Fluorometholone bulk offered by PFIZER

    Find a price of Hydrocortisone bulk offered by PFIZER

    Find a price of Hydrocortisone Sodium Succinate bulk offered by PFIZER

    Find a price of Hydrogen Peroxide bulk offered by PFIZER

    Find a price of Hydroxyprogesterone Caproate bulk offered by PFIZER

    Find a price of Ibuprofen bulk offered by PFIZER

    Find a price of Idarubicin Hydrochloride bulk offered by PFIZER

    Find a price of Lysergic Acid bulk offered by PFIZER

    Find a price of Lysine Hydrochloride bulk offered by PFIZER

    Find a price of Meclofenamic Acid bulk offered by PFIZER

    Find a price of Medroxyprogesterone Acetate bulk offered by PFIZER

    Find a price of Medrysone bulk offered by PFIZER

    Find a price of Menogarol bulk offered by PFIZER

    Find a price of Metergoline bulk offered by PFIZER

    Find a price of Methacycline Hydrochloride bulk offered by PFIZER

    Find a price of Methaqualone bulk offered by PFIZER

    Find a price of Methotrexate bulk offered by PFIZER

    Find a price of Methyl Testosterone bulk offered by PFIZER

    Find a price of Methylprednisolone Hemisuccinate bulk offered by PFIZER

    Find a price of Minocycline Hydrochloride bulk offered by PFIZER

    Find a price of Minoxidil bulk offered by PFIZER

    Find a price of Mithramycin bulk offered by PFIZER

    Find a price of Neomycin Sulfate bulk offered by PFIZER

    Find a price of Nicotine bulk offered by PFIZER

    Find a price of Nystatin bulk offered by PFIZER

    Find a price of Olsalazine bulk offered by PFIZER

    Find a price of Oxytetracycline Calcium bulk offered by PFIZER

    Find a price of Oxytetracycline Dihydrate bulk offered by PFIZER

    Find a price of Oxytetracycline Hydrochloride bulk offered by PFIZER

    Find a price of Penicillin G Benzathine bulk offered by PFIZER

    Find a price of Penicillin G Procaine bulk offered by PFIZER

    Find a price of Penicillin V Potassium bulk offered by PFIZER

    Find a price of Pentostatin bulk offered by PFIZER

    Find a price of Phenytoin Sodium bulk offered by PFIZER

    Find a price of Polyethylene Glycol Monostearate bulk offered by PFIZER

    Find a price of Prednisolone bulk offered by PFIZER

    Find a price of Prednisolone Sodium Phosphate bulk offered by PFIZER

    Find a price of Prednisone bulk offered by PFIZER

    Find a price of Prednisone Acetate bulk offered by PFIZER

    Find a price of Reserpine bulk offered by PFIZER

    Find a price of Rifabutin bulk offered by PFIZER

    Find a price of Silicon Dioxide API bulk offered by PFIZER

    Find a price of Spectinomycin HCl bulk offered by PFIZER

    Find a price of Streptomycin bulk offered by PFIZER

    Find a price of Tazobactam Sodium bulk offered by PFIZER

    Find a price of Testolactone bulk offered by PFIZER

    Find a price of Testosterone Enanthate bulk offered by PFIZER

    Find a price of Tetracycline bulk offered by PFIZER

    Find a price of Tetracycline Hydrochloride bulk offered by PFIZER

    Find a price of Tinidazole bulk offered by PFIZER

    Find a price of Tirilazad bulk offered by PFIZER

    Find a price of Tolbutamide bulk offered by PFIZER

    Find a price of Tranexamic Acid bulk offered by PFIZER

    Find a price of Treprostinil Sodium bulk offered by PFIZER

    Find a price of Triazolam bulk offered by PFIZER

    Find a price of Troleandomycin bulk offered by PFIZER

    Find a price of Vancomycin Hydrochloride bulk offered by PFIZER

    Find a price of Vidarabine bulk offered by PFIZER

    Find a price of Viomycin Sulfate bulk offered by PFIZER

    Find a price of Zinc Gluconate API bulk offered by PFIZER

    Find a price of 16-METHYLDIOLONE ACETATE AND S.D. VII) 9(11)-ANHYDRO-16a METHYLPREDNIS bulk offered by PFIZER

    Find a price of IODODOXORUBICIN HCL BULK DRUG SUBSTANCE bulk offered by PFIZER

    Find a price of METHODS, FACILS & CONTRLS bulk offered by PFIZER

    Find a price of VIRAL AND BACTERIAL VACCINES bulk offered by PFIZER

    Find a price of FACILITY, PERSONNEL AND OPERATING PROCEDURES IN STOCKHOLM, SWEDEN bulk offered by PFIZER

    Find a price of PERSONNEL FACILITIES AND OPERATING PROCEDURE bulk offered by PFIZER

    Find a price of FACILITY AND OPERATING PROCEDURES AT THE BRUNNA FACILITY IN KUNGSANGEN, SWEDEN bulk offered by PFIZER

    Find a price of FACILITIES, PERSONNEL & EQUIPMENT IN SANDWICH, KENT, ENGLAND bulk offered by PFIZER

    Find a price of CLINICAL INVESTIGATION-- CI-395 bulk offered by PFIZER

    Find a price of FACILITIES & GENERAL OPERATING PROCEDURES (SANDY, UTAH LOCATION) bulk offered by PFIZER

    Find a price of CLINICAL INVESTIGATION--CI 384 bulk offered by PFIZER

    Find a price of AT THE CHRISTIANSTED, ST. CROIX LOCATION bulk offered by PFIZER

    Find a price of CLINICAL INVESTIGATION --CI 442 bulk offered by PFIZER

    Find a price of MANUFACTURING ,PACKAGING AND CONTROLS PROCEDURES-THIS IS A VET MED DMF bulk offered by PFIZER

    Find a price of MANUFACTURING FACILITIES IN COLUMBUS, OHIO bulk offered by PFIZER

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN HILLEROD, DENMARK. bulk offered by PFIZER

    Find a price of HYDROXY ACID bulk offered by PFIZER

    Find a price of FACILITIES AND CONTROLS IN WEST SUSSEX, U.K. bulk offered by PFIZER

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN ARNPRIOR, ONTARIO, CANADA. bulk offered by PFIZER

    Find a price of PELLETHANE MDI BASED URETHANE ELASTOMER bulk offered by PFIZER

    Find a price of CAPSULE PLANT OPERATION AT THE DETROIT, MICHIGAN FACILITY bulk offered by PFIZER

    Find a price of ARA-CYTIDINE 5 - BENZOATE (U - 32,072E) bulk offered by PFIZER

    Find a price of (U-31, 583) 1-B-D-ARABINOFURANOSYLCYTOSINE 5'-PALMITATE bulk offered by PFIZER

    Find a price of MANUFACTURING SITE FACILITIES OPERATING PROCEDURES AND PERSONNEL OF THE GS/API PROCESS R&D PLANT IN NERVIANO ITALY bulk offered by PFIZER

    Find a price of METHODS, FACILITIES AND CONTROLS bulk offered by PFIZER

    Find a price of VIRAL AND BACTERIAL VACCINE bulk offered by PFIZER

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES bulk offered by PFIZER

    Find a price of 17-DESOXY OXIDO bulk offered by PFIZER

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN GWENT, UNITED KINGDOM. bulk offered by PFIZER

    Find a price of FACILITY AND OPERATING PROCEDURES IN STOCKHOLM, SWEDEN bulk offered by PFIZER

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN MILAN, ITALY. bulk offered by PFIZER

    Find a price of CLINICAL INVESTIGATION--CI-383 bulk offered by PFIZER

    Find a price of PERSONNEL, FACILITIES & GENERAL OPERATING PROCEDURES bulk offered by PFIZER

    Find a price of CLINICAL INVESTIGATIONS--CI 400 AND 421 bulk offered by PFIZER

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN PARSIPPANY, NEW JERSEY. bulk offered by PFIZER

    Find a price of CLINICAL INVESTIGATION--CI-446 bulk offered by PFIZER

    Find a price of PERSONNEL, FACILS & GEN OPER PROCEDS AT THE LITITZ, PA FACILITY bulk offered by PFIZER

    Find a price of GEN. INFO APPLICABLE TO THE FINE CHEMICAL OPERATIONS bulk offered by PFIZER

    Find a price of FACILS. & CONTROLS LOCATED IN FJARDO, PUERTO RICO FACILITY bulk offered by PFIZER

    Find a price of MANFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN JOHANNESHOV, SWEDEN. bulk offered by PFIZER

    Find a price of NSC-51173, (U-10955)--5A-ANDROSTAN-3-ONE,2A-FLUORO-17B-HYDROXY bulk offered by PFIZER

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES OF LARGE VOLUME PARENTERALS IN GLASS BOTTLES IN UPPSALS, SWEDEN. bulk offered by PFIZER

    Find a price of ANTIBIOTIC GENERAL INFORMATION bulk offered by PFIZER

    Find a price of SOLKETAL(GLYCEROL 1,2 - ISOPROPYLIDENE ETHER) bulk offered by PFIZER

    Find a price of QUALITY CONTROL INFORMATION FOR NDA ANTIBIOTIC bulk offered by PFIZER

    Find a price of U-32, 070E (25-HYDROXYCHOLECALCIFEROL) bulk offered by PFIZER

    Find a price of IODODOXORUBICIN HCL FOR INJECTION bulk offered by PFIZER

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN BRISTOL, TENNESSEE. bulk offered by PFIZER

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN UPPSALA, SWEDEN. bulk offered by PFIZER

    Find a price of BIZELESIN (U-77779) DRUG SUBSTANCE bulk offered by PFIZER

    Find a price of BULK CHEMICALS , METHOD OF PREPARATION bulk offered by PFIZER

    Find a price of FACILITY AND OPERATING PROCEDURES IN STRANGNAS, SWEDEN bulk offered by PFIZER

    Find a price of POLYMYXIN METHANE SULFONATE FOR TREAT. OF DISEASE IN POULTRY (VET) bulk offered by PFIZER

    Find a price of QUALIFICATIONS OF PARKE, DAVIS & CO. RESEARCH PERSONNEL bulk offered by PFIZER

    Find a price of CLINICAL INVESTIGATION--CI-462 bulk offered by PFIZER

    Find a price of CLINICAL INVESTIGATION--CI 344 bulk offered by PFIZER

    Find a price of MFG, PROCESS & PACK OF INDS IN MORRIS PLAINS, NJ FACIL (710 TABOR RD) bulk offered by PFIZER

    Find a price of CLINICAL INVESTIGATION--CI423 bulk offered by PFIZER

    Find a price of OLEANSOMYCIN AND COCCIDIOSTATS IN POULTRY FEED bulk offered by PFIZER

    Find a price of WARNER-LAMBERT, CAPS PLANT OPER, BROCKVILLE, ONTARIO, CAN FACILITY bulk offered by PFIZER

    Find a price of CLINICAL INVESTIGATION 461 bulk offered by PFIZER

    Find a price of STYRENE - MALEIC ACID COPOLYMER-TOXIC. DATA, CLIN REPTS & PHYSI CHARAC bulk offered by PFIZER

    Find a price of MANUFACTURING SITE, FACILITIES, OPERATING PROCEDURES AND PERSONNEL IN UPPSALA, SWEDEN. bulk offered by PFIZER

    Find a price of PACKAGING OPERATION bulk offered by PFIZER

    Find a price of W 3361, A LIQUID ANTACID FORMULATION ---CHITOSAN ANTACID bulk offered by PFIZER

    Find a price of COMBINED ADRENAL HORMONE ANTIBIOTIC THERAPY bulk offered by PFIZER

    Find a price of 1-DESOXYEPHEDRINE bulk offered by PFIZER

    Find a price of CI -404 - ACTINOBOLIN SULFATE bulk offered by PFIZER

    Find a price of Hydrocortisone Acetate bulk offered by PFIZER

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search